Early post-exposure and curative therapeutic strategies against COVID-19
CONCLUSION: Despite the evolution of variants, antivirals still appear to have activity and remain the first-line treatment for patients, in addition to vaccination.PMID:37993363 | DOI:10.1016/j.rmr.2023.10.007 (Source: Revue des Maladies Respiratoires)
Source: Revue des Maladies Respiratoires - November 22, 2023 Category: Respiratory Medicine Authors: K Jaffal B Davido Source Type: research
Evaluation of the efficacy and safety of oral N ‐acetylcysteine in patients with COVID‐19 receiving the routine antiviral and hydroxychloroquine protocol: A randomized controlled clinical trial
ConclusionThe NAC could be more effective as prophylactic or adjuvant therapy in stable non-severe cases of COVID-19 with a particularly positive role in the augmentation of O2 saturation and faster reduction of the CRP level and inflammation or could be effective for better controlling of COVID-19 or its therapy-related side effects. (Source: Immunity, Inflammation and Disease)
Source: Immunity, Inflammation and Disease - November 20, 2023 Category: Allergy & Immunology Authors: Najmolsadat Atefi,
Azadeh Goodarzi,
Taghi Riahi,
Niloofar Khodabandehloo,
Mahshid Talebi Taher,
Niloufar Najar Nobari,
Farnoosh Seirafianpour,
Zeinab Mahdi,
Amir Baghestani,
Rohollah Valizadeh Tags: ORIGINAL ARTICLE Source Type: research
Why does Paxlovid make things taste bitter?
Paxlovid can
prevent severe illness from COVID-19
, but it comes with a price: In many users, the antiviral drug leaves a weird, metallic aftertaste that can last for days—a condition nicknamed “Paxlovid mouth.”
Now, researchers say they’ve figured out why.
A component of Paxlovid activates one of the tongue’s bitter taste receptors even at low levels
, which may draw out the yuck factor, the team reports this month in
Biochemical and Biophysical Research Communications
. The work could lead to ways to alleviate the unpleasant side effect.
The study is a “good first ste...
Source: Science of Aging Knowledge Environment - November 20, 2023 Category: Geriatrics Source Type: research
A pilot study on Paxlovid therapy for hemodialysis patients with severe acute respiratory syndrome coronavirus 2 infections
AbstractWe aimed to investigate the safety and efficacy of nirmatrelvir/ritonavir (Paxlovid) therapy for hemodialysis-dependent patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Thirteen hemodialysis patients infected with the Omicron variant of SARS-CoV-2 from April 3 to May 30, 2022, were recruited. Laboratory parameters and chest CT (computed tomography) imaging were analyzed. The treatment group included six patients who received 150 mg/100 mg of Paxlovid orally once daily for 5 days, whereas the control group included seven patients who received basic treatment. No serious adverse r...
Source: Frontiers of Medicine - November 18, 2023 Category: General Medicine Source Type: research
Clinical efficacy of nirmatrelvir plus ritonavir in patients with COVID-19 and preexisting cardiovascular diseases
CONCLUSIONS: Our findings indicate that NMV-r to treat COVID-19 could reduce all-cause hospitalization and death in patients with CVDs.PMID:37965890 | DOI:10.1080/14787210.2023.2284367 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - November 15, 2023 Category: Infectious Diseases Authors: Ting-Hui Liu Jheng-Yan Wu Po-Yu Huang Wan-Hsuan Hsu Min-Hsiang Chuang Ya-Wen Tsai Chih-Cheng Lai Chun-Yen Huang Source Type: research
The impact of vaccination and outpatient treatment on the economic burden of covid-19 in the United States omicron era: a systematic literature review
CONCLUSIONS: Despite evidence gaps, findings from the SLR highlight the significant positive impact that vaccination and outpatient treatment have had on HCRU in the US, including periods of Omicron predominance. Continued research is needed to inform clinical and policy decision-making in the US as COVID-19 continues to evolve as an endemic disease.PMID:37964554 | DOI:10.1080/13696998.2023.2281882 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - November 15, 2023 Category: Health Management Authors: Vicki Pierre Florin Draica Manuela Di Fusco Jingyan Yang Solange Nunez-Gonzalez Joanna Kamar Santiago Lopez Mary M Moran Jennifer Nguyen Piedad Alvarez Ashley Cha-Silva Meghan Gavaghan Alon Yehoshua Naomi Stapleton Heather Burnett Source Type: research
Clinical efficacy of nirmatrelvir plus ritonavir in patients with COVID-19 and preexisting cardiovascular diseases
CONCLUSIONS: Our findings indicate that NMV-r to treat COVID-19 could reduce all-cause hospitalization and death in patients with CVDs.PMID:37965890 | DOI:10.1080/14787210.2023.2284367 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - November 15, 2023 Category: Infectious Diseases Authors: Ting-Hui Liu Jheng-Yan Wu Po-Yu Huang Wan-Hsuan Hsu Min-Hsiang Chuang Ya-Wen Tsai Chih-Cheng Lai Chun-Yen Huang Source Type: research
The impact of vaccination and outpatient treatment on the economic burden of covid-19 in the United States omicron era: a systematic literature review
CONCLUSIONS: Despite evidence gaps, findings from the SLR highlight the significant positive impact that vaccination and outpatient treatment have had on HCRU in the US, including periods of Omicron predominance. Continued research is needed to inform clinical and policy decision-making in the US as COVID-19 continues to evolve as an endemic disease.PMID:37964554 | DOI:10.1080/13696998.2023.2281882 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - November 15, 2023 Category: Health Management Authors: Vicki Pierre Florin Draica Manuela Di Fusco Jingyan Yang Solange Nunez-Gonzalez Joanna Kamar Santiago Lopez Mary M Moran Jennifer Nguyen Piedad Alvarez Ashley Cha-Silva Meghan Gavaghan Alon Yehoshua Naomi Stapleton Heather Burnett Source Type: research
GSE247541 Transcriptional changes in human pluripotent stem cell-derived cardiomyocytes induced by apilimod, remdesivir, ritonavir, and lopinavir treatment
Contributors : Nan Cao ; He Xu ; Ge Liu ; Jixing Gong ; Ying Zhang ; Shanshan GuSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe rapid development of safe and effective treatments for COVID-19 had become a top priority to fight against this spreading pandemic worldwide in 2019. 20% –30% of COVID-19 patients experience severe cardiovascular damage, patients with pre-existing heart complications are more likely to develop severe illness and have higher risk of death compared with patients without co-morbidities. In such a context, whether the repurposed drugs are at risk of i...
Source: GEO: Gene Expression Omnibus - November 15, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Oral Nirmatrelvir-Ritonavir Use and Clinical Outcomes in Pregnant Patients With Coronavirus Disease 2019 (COVID-19)
Obstet Gynecol. 2023 Nov 14. doi: 10.1097/AOG.0000000000005471. Online ahead of print.ABSTRACTWe conducted a retrospective cohort study of pregnant patients who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by RNA polymerase chain reaction test or home test who were counseled about taking nirmatrelvir-ritonavir if they were within 5 days of symptom onset. Obstetric and coronavirus disease 2019 (COVID-19) outcomes were compared between patients who did and did not take the medication. Overall, 114 individuals took nirmatrelvir-ritonavir and 323 did not. The cohorts were comparabl...
Source: Obstetrics and Gynecology - November 14, 2023 Category: OBGYN Authors: Bineta B Toure Aisvarya Panakam Sarah L Johns Sharlay K Butler Ruth E Tuomala Khady Diouf Source Type: research
